Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Barriers to FDA approvals, such as high application costs and lengthy review times, are also limiting, and there are currently 3800 filing generic drug applications awaiting FDA review. The FDA will be updating its structured approach to benefit-risk assessment in drug regulatory decision-making, because the current version covers only 2013-17.9 Th...
Alternative Titles
Full title
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1859469646
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1859469646
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(16)30653-2
